AU2003246740B2 - Use of new etonogestrel esters - Google Patents

Use of new etonogestrel esters Download PDF

Info

Publication number
AU2003246740B2
AU2003246740B2 AU2003246740A AU2003246740A AU2003246740B2 AU 2003246740 B2 AU2003246740 B2 AU 2003246740B2 AU 2003246740 A AU2003246740 A AU 2003246740A AU 2003246740 A AU2003246740 A AU 2003246740A AU 2003246740 B2 AU2003246740 B2 AU 2003246740B2
Authority
AU
Australia
Prior art keywords
etonogestrel
undecanoate
ment
testosterone
esters
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003246740A
Other languages
English (en)
Other versions
AU2003246740A1 (en
Inventor
Henrik De Nijis
Arij Jan Grootenhuis
Dirk Leysen
Jaap Van Der Louw
Hendrikus Adrianus Antonius Van Der Voort
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon NV
Original Assignee
Organon NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon NV filed Critical Organon NV
Publication of AU2003246740A1 publication Critical patent/AU2003246740A1/en
Assigned to N.V. ORGANON reassignment N.V. ORGANON Request for Assignment Assignors: AKZO NOBEL N.V.
Application granted granted Critical
Publication of AU2003246740B2 publication Critical patent/AU2003246740B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AU2003246740A 2002-05-30 2003-05-22 Use of new etonogestrel esters Ceased AU2003246740B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02077118 2002-05-30
EP02077118.4 2002-05-30
PCT/EP2003/050188 WO2003101374A2 (en) 2002-05-30 2003-05-22 Use of new etonogestrel esters

Publications (2)

Publication Number Publication Date
AU2003246740A1 AU2003246740A1 (en) 2003-12-19
AU2003246740B2 true AU2003246740B2 (en) 2009-01-08

Family

ID=29595013

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003246740A Ceased AU2003246740B2 (en) 2002-05-30 2003-05-22 Use of new etonogestrel esters

Country Status (26)

Country Link
US (1) US20050222114A1 (enExample)
EP (1) EP1513588B1 (enExample)
JP (1) JP2005532336A (enExample)
KR (1) KR20050005507A (enExample)
CN (1) CN1655848A (enExample)
AR (1) AR040129A1 (enExample)
AT (1) ATE394140T1 (enExample)
AU (1) AU2003246740B2 (enExample)
BR (1) BR0311248A (enExample)
CA (1) CA2487293A1 (enExample)
DE (1) DE60320786D1 (enExample)
ES (1) ES2305498T3 (enExample)
HR (1) HRP20041127A2 (enExample)
IL (1) IL165125A0 (enExample)
IS (1) IS7537A (enExample)
MX (1) MXPA04011798A (enExample)
NO (1) NO20044903L (enExample)
NZ (1) NZ536618A (enExample)
PE (1) PE20040042A1 (enExample)
PL (1) PL373295A1 (enExample)
RS (1) RS101004A (enExample)
RU (1) RU2322986C2 (enExample)
TW (1) TW200400041A (enExample)
UA (1) UA80703C2 (enExample)
WO (1) WO2003101374A2 (enExample)
ZA (1) ZA200409498B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200403065A (en) * 2002-05-30 2004-03-01 Akzo Nobel Nv New etonogestrel esters
US20130123523A1 (en) * 2011-11-10 2013-05-16 Klaus Nickisch Methods for the preparation of etonogestrel and desogestrel
DE102012211511A1 (de) * 2012-07-03 2014-01-09 Siemens Aktiengesellschaft Bestimmung der Eignung einer Ressource
BR112020007673A2 (pt) * 2017-10-19 2020-10-13 Evestra, Inc. contraceptivos pró-fármaco de progestina de ação prolongada
CN111057120B (zh) * 2019-12-27 2021-04-27 苏州翔实医药发展有限公司 一种依托孕烯衍生物a及其制备方法和用途
EP4164743A2 (en) * 2020-06-11 2023-04-19 The United States of America, as represented by The Secretary, Department of Health and Human Services Monomeric and oligomeric compound embodiments as contraceptives and therapies and methods of making and using the same

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0737477A1 (en) * 1993-12-27 1996-10-16 Akzo Nobel N.V. Percutaneously absorbable preparation
WO1997003709A1 (de) * 1995-07-17 1997-02-06 Schering Aktiengesellschaft Mittel zur transdermalen applikation enthaltend ester des 3-ketodegestrel
WO1999067271A1 (en) * 1998-06-19 1999-12-29 Akzo Nobel N.V. Testosterone derivative
WO1999067270A1 (en) * 1998-06-19 1999-12-29 Akzo Nobel N.V. Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone)
WO2000042942A2 (en) * 1999-01-26 2000-07-27 Place Virgil A Buccal drug delivery system for use in male contraception

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4227989A1 (de) * 1992-08-21 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
DE4240806A1 (de) * 1992-12-01 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 14alpha,17alpha-Ethanoestra-1,3,5(10)-trien-3,17beta-diol
JPH07101884A (ja) * 1993-10-01 1995-04-18 Sanei Gen F F I Inc 水溶性ヘミセルロースを含有する製剤
TW200403065A (en) * 2002-05-30 2004-03-01 Akzo Nobel Nv New etonogestrel esters

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0737477A1 (en) * 1993-12-27 1996-10-16 Akzo Nobel N.V. Percutaneously absorbable preparation
WO1997003709A1 (de) * 1995-07-17 1997-02-06 Schering Aktiengesellschaft Mittel zur transdermalen applikation enthaltend ester des 3-ketodegestrel
WO1999067271A1 (en) * 1998-06-19 1999-12-29 Akzo Nobel N.V. Testosterone derivative
WO1999067270A1 (en) * 1998-06-19 1999-12-29 Akzo Nobel N.V. Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone)
WO2000042942A2 (en) * 1999-01-26 2000-07-27 Place Virgil A Buccal drug delivery system for use in male contraception

Also Published As

Publication number Publication date
NZ536618A (en) 2007-06-29
RU2322986C2 (ru) 2008-04-27
EP1513588A2 (en) 2005-03-16
AR040129A1 (es) 2005-03-16
RU2004138809A (ru) 2005-06-10
US20050222114A1 (en) 2005-10-06
IL165125A0 (en) 2005-12-18
PE20040042A1 (es) 2004-01-31
DE60320786D1 (de) 2008-06-19
BR0311248A (pt) 2005-03-15
UA80703C2 (en) 2007-10-25
HK1072568A1 (en) 2005-09-02
TW200400041A (en) 2004-01-01
WO2003101374A2 (en) 2003-12-11
CN1655848A (zh) 2005-08-17
CA2487293A1 (en) 2003-12-11
PL373295A1 (en) 2005-08-22
WO2003101374A3 (en) 2004-02-26
MXPA04011798A (es) 2005-03-31
AU2003246740A1 (en) 2003-12-19
IS7537A (is) 2004-11-18
RS101004A (sr) 2006-10-27
ES2305498T3 (es) 2008-11-01
NO20044903L (no) 2005-02-25
HRP20041127A2 (en) 2005-02-28
EP1513588B1 (en) 2008-05-07
JP2005532336A (ja) 2005-10-27
KR20050005507A (ko) 2005-01-13
ZA200409498B (en) 2006-05-31
ATE394140T1 (de) 2008-05-15

Similar Documents

Publication Publication Date Title
CA2487722C (en) New etonogestrel esters
EP1513588B1 (en) Use of new etonogestrel esters
US20060094698A1 (en) Self-administered contraceptive injection of oily solution
HK1072568B (en) Use of new etonogestrel esters
HK1072609B (en) New etonogestrel esters
Loriaux¹ Lynnette K. Nieman, 1 George rge P. Chrousos, 1 Charles

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: N.V. ORGANON

Free format text: FORMER APPLICANT(S): AKZO NOBEL N.V.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired